Hyperthyroidism is a clinical condition characterized by low thyroid-stimulating hormone (TSH) blood levels and normal or higher blood levels of triiodothyronine (FT3) and thyroxine (FT4). Typically nervousness, heat intolerance, palpitations, and weight loss despite increased appetite are the main symptoms and signs of hyperthyroidism affecting female sex in most cases [1, 2]. Graves’ disease can explain the majority of hyperthyroidism diagnosis [3], while autonomously functioning thyroid nodules (AFTN) represent a secondary, but not negligible, cause of hyperthyroidism [4].
Radioactive iodine (RAI) administration and surgery are the main treatment options for AFTN, but recently radiofrequency ablation (RFA) has been proposed as an alternative [5]. Radiofrequency is widely used for the treatment of non-functioning benign thyroid nodules (NFTN) due to its mini-invasive profile, the ability to reduce nodule volume and low rate of complications. However, clinical experience with RFA as a therapy for AFTN is limited, particularly regarding the availability of comprehensive follow-up data [6,7,8,9,10].
RAI therapy is based on the natural capacity of thyroid cells to take iodine trough sodium iodine symporter (NIS) and [131]-iodine β-emission able to induce cell death [11,12,13,14]. RAI is considered a cornerstone for the treatment of hyperfunctioning thyroid diseases right from its introduction in clinical practice to nowadays, acting as a valid alternative to surgery [5, 15,16,17,18]. Some advantages over surgery, stemming from RAI’s good safety and tolerability profile, the theragnostic capability, and the lower healthcare cost, have significantly contributed to its clinical use success [5].
In a recent systematic review and comparative meta‑analysis, Giovanella and co-workers compares RFA to RAI as standard of care [19]. The study included 23 articles comparing the response rate of RAI and RFA for the treatment of AFTN. Hypothyroidism or euthyroidism was defined as primary outcome, while nodule volume reduction and TSH level modification were defined as secondary outcome. Primary and secondary outcomes were evaluated between 3 and 6 months, between 6 and 12 months, and at the end of the follow-up period (if > 12 months). A total of 296 patients treated with RFA and 1042 patients who received RAI therapy for AFTN were included into the statistical analysis. Some studies considered for the meta-analysis carried out by Giovannella and co-workers, including a total of 141 patients, directly compared RAI and RFA. In the pooled data analysis, they found a higher success rate with RAI therapy compared to RFA, along with a greater risk of failure associated with RFA treatment. However, the latter finding did not reach statistical significance.
The analysis of the entire population of 1338 patients revealed a pooled success rate of 94% among those treated with RAI administration, while only 59% of the patients who underwent RFA reached the primary outcome.
This study confirms the superiority of RAI therapy over the newly proposed RFA for the treatment of AFTN. Hyperthyroidism poses a significant threat if left untreated for an extended period and is linked to higher cardiovascular disease risk [20,21,22,23], osteoporosis, and potentially to increased risk of certain tumor development [24,25,26]. Therefore, a prompt correction of this condition is mandatory.
In addition, RFA is hardly free of side effects that are various and not negligible [27,28,29] compared with those related with RAI administration [30,31,32,33]. RFA is a novel introduction in clinical practice requiring technical improvements and a deeper understanding of its potential and limitations. RAI comes with an extensive clinical use along with a large number of treated patients. Several studies have been conducted to better clarify its role, its safety, and efficacy in either AFTN or other thyroid pathologies cure [4, 17, 34,35,36,37]. While radiation exposure can be a point of concern, the overall safety and tolerability of RAI administration along with its specificity and efficacy might easily still make RAI therapy the treatment of choice for AFTN.
References
Durante, C.; Hegedus, L.; Czarniecka, A.; Paschke, R.; Russ, G.; Schmitt, F.; Soares, P.; Solymosi, T.; Papini, E. European Thyroid Association clinical practice guidelines for thyroid nodule management. Eur Thyroid J 2020;ETJ-23–0067. https://doi.org/10.1530/ETJ-23-0067.
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343–421. https://doi.org/10.1089/thy.2016.0229.
Piccardo A, Ugolini M, Altrinetti V, Righi S, Fiz F, Foppiani L, Giovanella L. Radioiodine therapy of Graves’ disease. Q J Nucl Med Mol Imaging. 2021;65:132–7. https://doi.org/10.23736/S1824-4785.21.03337-9.
Wiersinga WM, Poppe KG, Effraimidis G. Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes Endocrinol. 2023;11:282–98. https://doi.org/10.1016/S2213-8587(23)00005-0.
Campennì A, Avram AM, Verburg FA, Iakovou I, Hänscheid H, de Keizer B, Petranović Ovčariček P, Giovanella L. The EANM guideline on radioiodine therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2023;50:3324–48. https://doi.org/10.1007/s00259-023-06274-5.
Bom WJ, Joosten FBM, van Borren MMGJ, Bom EP, van Eekeren RRJP, de Boer H. Radiofrequency ablation for symptomatic, non-functioning, thyroid nodules: a single-center learning curve. Endocr Connect. 2022;11:e210304. https://doi.org/10.1530/EC-21-0304.
Cesareo R, Palermo A, Pasqualini V, Manfrini S, Trimboli P, Stacul F, Fabris B, Bernardi S. Radiofrequency ablation on autonomously functioning thyroid nodules: a critical appraisal and review of the literature. Front Endocrinol (Lausanne). 2020;11:317. https://doi.org/10.3389/fendo.2020.00317.
Kim Y-J, Baheti A, Huber TC. Radiofrequency ablation of solid benign thyroid nodules. Tech Vasc Interv Radiol. 2022;25:100819. https://doi.org/10.1016/j.tvir.2022.100819.
Xiaoyin T, Bingwei L, Min D, Yan L, Ping L, Bo Z. Preliminary results of utrasound-guided percutaneous radiofrequency ablation in the treatment of refractory non-nodular hyperthyroidism. Cardiovasc Intervent Radiol. 2023;46:1015–22. https://doi.org/10.1007/s00270-023-03401-5.
Sim JS, Baek JH, Lee J, Cho W, Jung SI. Radiofrequency ablation of benign thyroid nodules: depicting early sign of regrowth by calculating vital volume. Int J Hyperthermia. 2017;33:905–10. https://doi.org/10.1080/02656736.2017.1309083.
Klain M, Nappi C, Zampella E, Cantoni V, Green R, Piscopo L, Volpe F, Manganelli M, Caiazzo E, Petretta M, et al. Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48:4437–44. https://doi.org/10.1007/s00259-021-05440-x.
Klain M, Nappi C, Maurea S, De Risi M, Volpe F, Caiazzo E, Piscopo L, Manganelli M, Schlumberger M, Cuocolo A. Management of differentiated thyroid cancer through nuclear medicine facilities during Covid-19 emergency: the telemedicine challenge. Eur J Nucl Med Mol Imaging. 2021;48:831–6. https://doi.org/10.1007/s00259-020-05041-0.
Klain M, Zampella E, Manganelli M, Gaudieri V, Nappi C, D’Antonio A, Piscopo L, Volpe F, Pace L, Schlumberger M, et al. Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancer. Endocrine. 2021;71:378–84. https://doi.org/10.1007/s12020-020-02379-1.
Khan MSA, Hussain A, Ahmad S, Shah MH. Outcomes of radioactive iodine (131I) therapy among hyperthyroid patients. Pak J Med Sci. 2023;39:1685–9. https://doi.org/10.12669/pjms.39.6.7567.
Chapman EM, Evans RD. The treatment of hyperthyroidism with radioactive iodine. J Am Med Assoc. 1946;131:86–91. https://doi.org/10.1001/jama.1946.02870190010003.
Sweeney BJ, Daughaday WH, Gottlieb L, Scott WG, MacBRYDE CM. Radioactive iodine therapy of hyperthyroidism: determination of optimum dosage. South Med J. 1951;44:648–54. https://doi.org/10.1097/00007611-195107000-00015.
Poppe K, Bisschop P, Fugazzola L, Minziori G, Unuane D, Weghofer A. 2021 European Thyroid Association guideline on thyroid disorders prior to and during assisted reproduction. Eur Thyroid J. 2021;9:281–95. https://doi.org/10.1159/000512790.
Thuillier P, Benisvy D, Ansquer C, Corvilain B, Mirallié E, Taïeb D, Borson-Chazot F, Lussey-Lepoutre C. SFE-AFCE-SFMN 2022 Consensus on the management of thyroid nodules: what is the role of functional imaging and isotopic treatment? Ann Endocrinol (Paris). 2022;83:401–6. https://doi.org/10.1016/j.ando.2022.10.008.
Giovanella L, Garo ML, Campenní A, Ovčariček PP. Radioiodine versus radiofrequency ablation to treat autonomously functioning thyroid nodules: a systematic review and comparative meta-analysis. Eur J Nucl Med Mol Imaging. 2024. https://doi.org/10.1007/s00259-024-06625-w.
Paschou SA, Bletsa E, Stampouloglou PK, Tsigkou V, Valatsou A, Stefanaki K, Kazakou P, Spartalis M, Spartalis E, Oikonomou E, et al. Thyroid disorders and cardiovascular manifestations: an update. Endocrine. 2022;75:672–83. https://doi.org/10.1007/s12020-022-02982-4.
Osman F, Franklyn JA, Holder RL, Sheppard MC, Gammage MD. Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study. J Am Coll Cardiol. 2007;49:71–81. https://doi.org/10.1016/j.jacc.2006.08.042.
Beyer C, Plank F, Friedrich G, Wildauer M, Feuchtner G. Effects of hyperthyroidism on coronary artery disease: a computed tomography angiography study. Can J Cardiol. 2017;33:1327–34. https://doi.org/10.1016/j.cjca.2017.07.002.
Wongcharoen W, Lin Y-J, Chang S-L, Lo L-W, Hu Y-F, Chung F-P, Chong E, Chao T-F, Tuan T-C, Chang Y-T, et al. History of hyperthyroidism and long-term outcome of catheter ablation of drug-refractory atrial fibrillation. Heart Rhythm. 2015;12:1956–62. https://doi.org/10.1016/j.hrthm.2015.06.004.
Petranović Ovčariček P, Verburg FA, Hoffmann M, Iakovou I, Mihailovic J, Vrachimis A, Luster M, Giovanella L. Higher thyroid hormone levels and cancer. Eur J Nucl Med Mol Imaging. 2021;48:808–21. https://doi.org/10.1007/s00259-020-05018-z.
Hellevik AI, Åsvold BO, Bjøro T, Romundstad PR, Nilsen TIL, Vatten LJ. Thyroid function and cancer risk: a prospective population study. Cancer Epidemiol Biomark Prev. 2009;18:570–4. https://doi.org/10.1158/1055-9965.EPI-08-0911.
Khan SR, Chaker L, Ruiter R, Aerts JGJV, Hofman A, Dehghan A, Franco OH, Stricker BHC, Peeters RP. Thyroid function and cancer risk: the Rotterdam study. J Clin Endocrinol Metab. 2016;101:5030–6. https://doi.org/10.1210/jc.2016-2104.
Abd-Elsayed A, Loebertman M, Huynh P, Urits I, Viswanath O, Sehgal N. The long-term efficacy of radiofrequency ablation with and without steroid injection. Psychopharmacol Bull. 2020;50:11–6.
Sanghai S, Henrikson CA. Radiofrequency ablation-to insure or not to insure is the question. J Cardiovasc Electrophysiol. 2022;33:1513–4. https://doi.org/10.1111/jce.15499.
Sinclair CF, Bastien AJ, Ho AS. Radiofrequency ablation (RFA) compared to observation for benign thyroid nodules: emerging considerations for judicious use. Curr Opin Endocrinol Diabetes Obes. 2022;29:449–55. https://doi.org/10.1097/MED.0000000000000739.
Fard-Esfahani A, Emami-Ardekani A, Fallahi B, Fard-Esfahani P, Beiki D, Hassanzadeh-Rad A, Eftekhari M. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun. 2014;35:808–17. https://doi.org/10.1097/MNM.0000000000000132.
Almeida JP, Sanabria AE, Lima ENP, Kowalski LP. Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head Neck. 2011;33:686–90. https://doi.org/10.1002/hed.21520.
Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw. 2010;8:1277–86. https://doi.org/10.6004/jnccn.2010.0094. quiz 1287.
Klain M, Zampella E, Piscopo L, Volpe F, Manganelli M, Masone S, Pace L, Salvatore D, Schlumberger M, Cuocolo A. Long-term prognostic value of the response to therapy assessed by laboratory and imaging findings in patients with differentiated thyroid cancer. Cancers (Basel). 2021;13:4338. https://doi.org/10.3390/cancers13174338.
Berdelou A, Lamartina L, Klain M, Leboulleux S, Schlumberger M. Treatment of refractory thyroid cancer. Endocr Relat Cancer. 2018;25:R209–23. https://doi.org/10.1530/ERC-17-0542.
Porcelli T, Luongo C, Sessa F, Klain M, Masone S, Troncone G, Bellevicine C, Schlumberger M, Salvatore D. Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution. Endocrine. 2021;73:358–66. https://doi.org/10.1007/s12020-021-02634-z.
Nappi C, Klain M, Cantoni V, Green R, Piscopo L, Volpe F, Maurea S, Petretta M, Cuocolo A. Risk of primary breast cancer in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2022;49:1630–9. https://doi.org/10.1007/s00259-021-05625-4.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. https://doi.org/10.1089/thy.2015.0020.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
Institutional Review Board approval was not required because the paper is an editorial.
Consent to participate
Not applicable.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Volpe, F., Nappi, C., Ponsiglione, A. et al. Radiofrequency ablation versus radioactive iodine: the race for the best cure. Eur J Nucl Med Mol Imaging (2024). https://doi.org/10.1007/s00259-024-06679-w
Published:
DOI: https://doi.org/10.1007/s00259-024-06679-w